GeneDx Net Income Per Share from 2010 to 2024

WGS Stock   57.79  0.40  0.69%   
GeneDx Holdings Net Loss yearly trend continues to be comparatively stable with very little volatility. Net Loss will likely drop to -7.59 in 2024. From the period from 2010 to 2024, GeneDx Holdings Net Loss quarterly data regression had mean square error of 174.1 B and mean deviation of  197,237. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(7.23)
Current Value
(7.59)
Quarterly Volatility
409.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 3.1 M or Depreciation And Amortization of 31.4 M, as well as many indicators such as Price To Sales Ratio of 0.31, Dividend Yield of 0.0 or PTB Ratio of 0.52. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
  
Check out the analysis of GeneDx Holdings Correlation against competitors.

Latest GeneDx Holdings' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of GeneDx Holdings Corp over the last few years. It is GeneDx Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Pretty Stable
   Net Income Per Share   
       Timeline  

GeneDx Net Income Per Share Regression Statistics

Arithmetic Mean(105,676)
Coefficient Of Variation(387.25)
Mean Deviation197,237
Median(4.26)
Standard Deviation409,229
Sample Variance167.5B
Range1.6M
R-Value(0.19)
Mean Square Error174.1B
R-Squared0.03
Significance0.51
Slope(16,984)
Total Sum of Squares2.3T

GeneDx Net Income Per Share History

2024 -7.59
2023 -7.23
2022 -53.63
2021 -74.93
2020-1.6 M

About GeneDx Holdings Financial Statements

GeneDx Holdings shareholders use historical fundamental indicators, such as Net Income Per Share, to determine how well the company is positioned to perform in the future. Although GeneDx Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in GeneDx Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on GeneDx Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(7.23)(7.59)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.